Juno Therapeutics

Three cancer research powerhouses form immunotherapy startup

Image: Dr. Larry Corey

December 4, 2013

For decades, Fred Hutch has been known for innovative approaches that use the immune system to treat cancer and save lives. Now, the Hutch is advancing its legacy in immunotherapy by means of a new Seattle biotechnology company that is a unique collaboration among scientists at the Hutch, Memorial Sloan-Kettering Cancer Center in New York and Seattle Children’s Research Institute. Read more >

 

Social stories about Juno Therapeutics

December 4, 2013

The story of Juno Therapeutics is all over social media. See the latest social posts and pages shared from the web, Twitter, Facebook, YouTube and Google+ via Storify.  Read more >

Leading cancer research centers team up to launch biotech startup

Image: Juno Therapeutics

December 4, 2013

Fred Hutch and Memorial Sloan-Kettering Cancer Center, along with pediatric partner Seattle Children’s Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer. Read the press release >

Frequently asked questions about Juno Therapeutics

December 4, 2013

Why are three leading cancer research organizations joining forces in a biotech startup? How much funding does Juno have? What is adoptive T-cell therapy? Get answers to FAQs.  Read more >
 

Juno Therapeutics grabs $120M to coax immune system to fight cancer

December 3, 2013

Today, after years of ups and downs, one of the biggest bets ever on a biotech startup is being made on a new immunotherapy company from Seattle and New York called Juno Therapeutics. By Luke Timmerman, Xconomy Read the story >
 

Cancer centers, longtime rivals, launch company to develop new drug

December 3, 2013

Two major cancer centers -- Fred Hutch and Memorial Sloan-Kettering -- joined forces and launched a company to develop a new treatment showing promise in early human trials. By Ron Winslow, The Wall Street Journal  Read the story >

Note: Only WSJ.com subscribers can access this story.
 

Learn more about Juno Therapeutics

Juno's leadership includes some of the world's leading immunotherapy researchers, accomplished venture capital investors and experienced global leaders. Find out about Juno's scientific background and how the team is working with the Hutch, Memorial Sloan-Kettering and Seattle Children's at their website. Visit JunoTherapeutics.com >
 

The promise of immunotherapy

Fred Hutch researchers are renowned for developing successful treatments that harness the immune system to fight cancer, much as it naturally eliminates everyday infections like the common cold. Today, we continue to lead this revolutionary field, called immunotherapy, which is yielding effective cancer treatments with far fewer side effects than conventional drugs, radiation or surgery.   Learn more >